Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service

References

• Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009;28:287
   PubMedGoogle Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6
   PubMed Web of Science ®Google Scholar
• Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132-8
   PubMed Web of Science ®Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:455-63
   PubMed Web of Science ®Google Scholar
• Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology 2004;64(Suppl 6A):2-6
   Google Scholar
• Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001;57:1044-50
   PubMed Web of Science ®Google Scholar
• Robinson D, Pearce KF, Preisser JS, et al. Relationship between patient reports of urinary incontinence symptoms and quality of life measures. Obstet Gynecol 1998;91:224-8
   PubMed Web of Science ®Google Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6(11 Suppl):S574-9
   PubMed Web of Science ®Google Scholar
• Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology 2010;75:526-32
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188(6 Suppl):2455-63
   PubMed Web of Science ®Google Scholar
• Ohtake A, Sato S, Sasamata M, et al. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. J Pharmacol Sci 2010;112:135-41
   Google Scholar
• Anderson RU, MacDiarmid S, Kell S, et al. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:502-11
   PubMed Web of Science ®Google Scholar
• Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-10
   PubMed Web of Science ®Google Scholar
• Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2009;105:58-66
   Google Scholar
• Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005;23:248-52
   PubMed Web of Science ®Google Scholar
• Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011;65:567-85
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012;110:1767-74
   PubMed Web of Science ®Google Scholar
• Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 2014;191:1003-8
   PubMed Web of Science ®Google Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2009;105:1276-82
   PubMedGoogle Scholar
• Campbell UB, Stang P, Barron R. Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. Value Health 2008;11:726-32
   PubMed Web of Science ®Google Scholar
• Imran M, Najmi AK, Tabrez S. Mirabegron for overactive bladder: a novel, first-in-class beta3-agonist therapy. Urol J 2013;10:935-40
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283-95
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Bhosle MJ, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J Urol 2006;175:1067-71
   PubMed Web of Science ®Google Scholar
• Office for National Statistics UK. Population estimates for England and Wales, Mid 2011. Table 3 – Mid-2011 population estimates: England and Wales; estimated resident population by single year of age and sex; based on the results of the 2011 Census. 2012. ONS is in Newport, South Wales. http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-262039. Accessed June 20, 2014
   Google Scholar
• Cardozo L, Thorpe A, Warner J, et al. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int 2010;106:506-14
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013;82:313-20
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95
   PubMed Web of Science ®Google Scholar
• Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2013;65:755-65
   Google Scholar
• British National Formulary, 2012. London. http://www.bnf.org/bnf/index.htm. Accessed December 2013
   Google Scholar
• Gopal M, Haynes K, Bellamy SL, et al. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008;112:1311-18
   PubMed Web of Science ®Google Scholar
• Personal Social Services Research Unit. Unit Costs of Health and Social Care. 2010. ONS is in Newport, South Wales. http://www.pssru.ac.uk/pdf/uc/uc2010/uc2010_s10.pdf. Accessed June 20, 2014
   Google Scholar
• Office for National Statistics UK. Consumer Price Indices, September 2012. Statistical Bulletin 2012:1-28
   Google Scholar
• UK Reference Costs 2011–2012. UK Department of Health, London, UK. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_133578.xls. Accessed June 20, 2014
   Google Scholar
• Eurostat. Purchasing power parities (PPs), price level indices and real expenditures for ESA95 aggregates. 2012. eurostat, Luxembourg. http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=prc_ppp_ind&lang=en. Accessed June 20, 2014
   Google Scholar
• Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009;103:202-9
   PubMed Web of Science ®Google Scholar
• Arlandis-Guzman S, Errando-Smet C, Trocio J, et al. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. BMC Urol 2011;11:9
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Clinical Guidelines. Urinary incontinence (CG40). 2006. NICE, London. http://www.nice.org.uk/CG40. Accessed June 20, 2014
   Google Scholar
• National Collaborating Centre for Women’s and Children’s Health. Urinary incontinence in women: the management of urinary incontinence in women. London. http://www.ncc-wch.org.uk/guidelines/guidelines-programme/guidelines-programme-published/urinary-incontinence/. Accessed September 2013
   Google Scholar
• National Institute for Health and Care Excellence. Technology appraisals. Overactive bladder – mirabegron (TA290). 2013. NICE, London. http://guidance.nice.org.uk/TA290. Accessed June 20, 2014
   Google Scholar
• Kobelt G, Borgstrom F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 2003;91:190-5
   PubMed Web of Science ®Google Scholar